Polyclonal Anti-human

Casein Kinase 1d Antiserum

The casein kinase 1 (CK1) family of protein kinases is common to all eukaryotic cells, with at least 15 sequence-distinct isoforms currently known.  Although the isoforms differ in tissue distribution and subcellular localization, CK1 kinases share several characteristics in that they exhibit Ser/Thr-specific protein kinase activity.  CK1 protein kinases contain  a nuclear localization signal and possess a kinesin homology domain, which is necessary for interactions with microtubules.  CK1 kinases are thought to participate in the regulation of membrane transport and in the DNA repair process.  CK1d has been implicated in the regulation of the tumor suppressor p53 and binds to microtubules, which suggests a regulatory role in mitosis.  CK1d has been reported to be elevated 30-fold in Alzheimer disease hippocampus and immunohistochemical localization has shown it to be associated generally with granulovacuolar degeneration and neurofibrillary tangles.  The overexpression of CK1d kinase and it’s association with tau-containing bodies suggests that it may play a role in the abnormal phosphorylation of tau.

A goat antiserum to a synthetic peptide that corresponds to amino acids 310-327 of the C-terminus of the human CK1d is currently available. This antiserum has been shown to be immunoreactive with the unconjugated immunizing peptide by ELISA.  It will also immunolabel granulovacuolar degeneration in formalin-fixed, paraffin-embedded AD hippocampus.  Western blot analysis identifies the 47 kD protein in both aged controk and AD brains.  This antibody should be  a valuable tool for scientists working to understand the role of CK1d in Alzheimer’s and other neurodegenerative diseases.

 This antiserum was produced using proprietary methodology whereby the peptide is attached to a carrier that elicits minimal immunoreactivity so that the antiserum has a higher degree of specificity for the peptide.  Since there is no overwhelming production of interfering antibodies to the carrier, this antiserum can routinely be used without further purification.  A control immune serum (Cat no. GPA018E) from a mock immunized animal is available to be used in conjunction with this antibody as well as the immunizing peptide (Cat no. HSP023C) which can be used to neutralize immunoreactivity.

Manufacturing Reference:

Southwest Immunology, Inc., unpublished results.